Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2017, Panacea Venture is a life sciences venture fund that spun out from Kleiner Perkins China. The firm operates from Shanghai, Boston, and Silicon Valley, managing a portfolio of over 30 companies. It specializes in supporting early-stage and growth-stage healthcare companies with a global investment strategy.
Panacea Venture invests in early-stage companies developing breakthrough technologies in sectors like therapeutics, small molecules, biologics, and cell and gene therapy. The fund targets investments in pre-seed, seed, seed-plus, Series A, and growth equity stages, with a particular emphasis on addressing unmet medical needs in Asia, especially China.
Notable investments include companies focused on next-generation immunotherapeutic modalities, innovative regenerative medicine, and treatments for neurodegenerative diseases. Their portfolio also encompasses R&D in animal vaccines and biological payload delivery technologies.
Email info@panaceaventure.com with your deck to pitch them directly.
Yes, Panacea Venture often leads investment rounds, particularly in early-stage companies within their focus sectors.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their investment thesis.
While specific fund size details are not disclosed, Panacea Venture manages a portfolio of over 30 companies, indicating a substantial capital base for investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.